Program
Insulin
Also written as “Inhaled Insulin”, “Subcutaneous Insulin” and “Inhaled insulin”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Non-alcoholic Fatty Liver Disease · Drug-Related Side Effects and Adverse Reactions, led by 14 companies.
Drug pageInsulin: every studyMany companies study it; this page follows only the 33 they lead. All 272 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 110 open or running | phase 4since Jan 3, 2007 | Aug 22, 2005 | none ahead |
| Oramedits history only | 50 open or running | phase 3since Oct 22, 2020 | Jun 19, 2013 | none ahead |
| Eli Lilly | 40 open or running | phase 3since Oct 19, 2006 | Jun 20, 2003 | none ahead |
| Oshadi Drug Administrationits history only | 20 open or running | phase 2since Jan 17, 2013 | Jan 17, 2013 | none ahead |
| Sanofiits history only | 20 open or running | phase 4since Jul 23, 2014 | Sep 2, 2010 | none ahead |
| Baxter Healthcareits history only | 10 open or running | phase 1since Jul 31, 2006 | Jul 31, 2006 | none ahead |
| CPEX Pharmaceuticalsits history only | 10 open or running | phase 2since Feb 23, 2009 | Feb 23, 2009 | none ahead |
| Generex Biotechnologyits history only | 10 open or running | phase 3since Apr 24, 2008 | Apr 24, 2008 | none ahead |
| Getz Pharmaits history only | 10 open or running | phase 4since Dec 16, 2021 | Dec 16, 2021 | none ahead |
| Nastech Pharmaceuticalits history only | 10 open or running | phase 2since Feb 7, 2008 | Feb 7, 2008 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 1since Sep 14, 2009 | Sep 14, 2009 | none ahead |
| QDoseits history only | 10 open or running | phase 1since Jan 24, 2007 | Jan 24, 2007 | none ahead |
| Roger Newits history only | 10 open or running | phase 2since Jun 19, 2024 | Jun 19, 2024 | none ahead |
| Sam Chun Dang Pharm.its history only | 11 open or running | phase 1since May 26, 2026 | May 26, 2026 | none ahead |
Also a collaborator on its studies: Integrium, Alkermes, Kowa, Nextrials, eResearch Technology, Hoffmann-La Roche, ACM Pivotal Global Central Laboratory and Novo Nordisk.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 20, 2003First study: phase 2 study in Diabetes Mellitus, Type 1First studyNCT00063128 · 119 enrolled · United States
- Dec 15, 2004Phase 2 study in Diabetes Mellitus, Type 2NCT00099515 · 97 enrolled · United States, Argentina, Portugal and more
- Oct 19, 2006Phase 3 study in Diabetes Mellitus, Type 2NCT00391209 · 379 enrolled · United States, Argentina, Austria and more
- Oct 27, 2015Phase 1 study in Diabetes Mellitus, Type 2NCT02588950 · 11 enrolled · United States
- Dec 9, 2019Named insulinINNProposed as its International Nonproprietary Name in WHO's List 122
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
All 4 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02588950Diabetes Mellitus, Type 2 · United States | 1 | Terminated | May 25, 2017 | 11 |
| NCT00391209Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more | 3 | Completed | May 2008 | 379 |
| NCT00099515Diabetes Mellitus, Type 2 · United States, Argentina, Portugal and more | 2 | Completed | 97 | |
| NCT00063128Diabetes Mellitus, Type 1 · United States | 2 | Completed | 119 |
How it is read
Names in the registry
- “Insulin”, 13 entries
- “Inhaled Insulin”, 5 entries
- “Subcutaneous Insulin”, 3 entries
- “Inhaled insulin”, 3 entries
- “Inhaled Insulin (Exubera)”, 2 entries
Codes read as this program: LY041001.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 22 studies
- Diabetes Mellitus, Type 1, 12 studies
- Diabetes Mellitus, 8 studies
- Non-alcoholic Fatty Liver Disease, 2 studies
- Drug-Related Side Effects and Adverse Reactions, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.